Scarica l'app Stockscreener
1.28
4.92%
0.06
Pre-mercato:
1.29
0.01
+0.78%
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics Inc (AKBA) Income Statement - TradingKey
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Akebia Therapeutics Inc (AKBA) Cash Flow - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.220| - TradingKey
Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey
Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Akebia Therapeutics, Inc. Revenue Breakdown – SWB:AX9 - TradingView
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Brokerages - MarketBeat
Akebia Therapeutics Inc (AKBA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Akebia Therapeutics (AKBA) Q2 2024 earnings summary - Quartr
Lobbying Update: $360,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 34.3% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Akebia: Vafseo Gains Traction, But It’s Still A Show-Me Story (Rating Downgrade) (AKBA) - Seeking Alpha
ETFs Investing in Akebia Therapeutics, Inc. Stocks - TradingView
Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Akebia Therapeutics (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Akebia Therapeutics Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesPre-Earnings Setup - DonanımHaber
Zacks Research Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics (AKBA) Proxy filing Summary - Quartr
Akebia Therapeutics (AKBA) Climbs 5.38% as Stock Nears Key Resistance ZoneWeak Sell Signals - dars.gov.et
AKBAAkebia Therapeutics Inc Options - Finviz
Chief Business Officer Erik Ostrowski Sold A Bunch Of Shares In Akebia Therapeutics - Moomoo
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $6.00 - GuruFocus
Akebia Therapeutics Fortifies Vafseo Patent Protection Through 2036, Strengthening Commercial ProspectsProduct Revenue Analysis - dars.gov.et
Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover - Stock Titan
H.C. Wainwright reiterates Akebia stock rating on trial results By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ostrowski Erik - Moomoo
Akebia TherapeuticsVoice Trial Meets Stopp - Moomoo
U.S. Renal Care and Akebia Therapeutics, Inc. Announce Interim Analysis of VOICE Trial Demonstrates Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo Versus ESA - marketscreener.com
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 - Yahoo Finance
Akebia (AKBA) VOICE Trial Halted Following Positive Interim Resu - GuruFocus
Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis - marketscreener.com
Akebia: VOICE trial stopped early after vadadustat shows superiority on primary composite endpoint - TradingView
Vafseo shows safer composite outcomes vs ESA in Akebia (AKBA) VOICE trial - Stock Titan
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA - marketscreener.com
Vafseo trial stops early after safety win in dialysis patients - Stock Titan
Form 144 Akebia Therapeutics For: 29 June By Investing.com - Investing.com Australia
Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therap - The National Law Review
Akebia Therapeutics, Inc. (AKBA) Investigation: Bronstein, Gewirt - The National Law Review
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
Price to book forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Enterprise value to EBIT forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Enterprise value to EBITDA forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Price to sales forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Akebia Therapeutics, Inc. Actuals & Estimates (NASDAQ:AKBA) - TradingView
AKBA Forecast — Price Target — Prediction for 2027 - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
0.30%
2.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):